The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAIREA Regulatory News (AIEA)

Share Price Information for AIREA (AIEA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 31.50
Bid: 31.00
Ask: 32.00
Change: -0.50 (-1.56%)
Spread: 1.00 (3.226%)
Open: 32.00
High: 32.00
Low: 31.50
Prev. Close: 32.00
AIEA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Rule 2.8 Announcement

22 May 2018 16:58

RNS Number : 9313O
James Halstead PLC
22 May 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE UK CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")

 

22 May 2018

 

James Halstead plc

 

("James Halstead" or the "Company")

 

Statement regarding Airea plc ("Airea")

 

No intention to bid statement

 

Further to the announcement of 2 May 2018, after careful consideration, the board of James Halstead confirms that it does not intend to make an offer for Airea pursuant to Rule 2.7 of the Code.

This is a statement to which Rule 2.8 of the Code applies.

Under Note 2 on Rule 2.8 of the Code, James Halstead reserves the right to set the restrictions in Rule 2.8 aside in the following circumstances:

(a) with the agreement of the board of Airea;

(b) if a third party announces a firm intention to make an offer for Airea;

(c) if Airea announces a "whitewash" proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or

(d) if there has been a material change of circumstances (as determined by the Panel on Takeovers and Mergers).

 

Enquiries:

 

James Halstead plc

Tel: 0161 767 2500

Mark Halstead, Chief Executive

Hudson Sandler

Tel: 020 7796 4133

Nick Lyon

Panmure Gordon (UK) Limited

(Financial Adviser and Joint Broker to James Halstead)

Tel: 020 7886 2500

Ben Thorne

Andrew Potts

Arden Partners (Joint Broker)

Tel: 020 7614 5900

Chris Hardie

 

Panmure Gordon (UK) Limited, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for James Halstead and no one else in connection with the Possible Offer and will not be responsible to anyone other than James Halstead for providing the protections afforded to its clients or for providing advice in relation to the Offer or any other matters referred to herein.

 

 

Publication of this announcement

 

A copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) at www.jameshalstead.com by no later than 12 noon (London time) on 23 May 2018, being the date following the date of this announcement.

 

Additional Information

 

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise. Any offer, if made, will be made solely by certain offer documentation which will contain the full terms and conditions of any offer, including details of how it may be accepted.

 

The distribution of this announcement in jurisdictions other than the United Kingdom and the availability of any offer to shareholders of James Halstead who are not resident in the United Kingdom may be affected by the laws of relevant jurisdictions. Therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom or shareholders of James Halstead who are not resident in the United Kingdom will need to inform themselves about, and observe, any applicable requirements.

 

Inside Information

 

The information contained within this announcement is deemed by James Halstead to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
OUPEASSAALEPEFF
Date   Source Headline
26th Mar 20247:00 amRNSFinal Results for the year ended 31 December 2023
11th Mar 20247:00 amRNSNotice of Results
24th Jan 20247:00 amRNSTrading update and £5.0m investment in facility
3rd Oct 20237:00 amRNSAppointment of Chief Financial Officer
28th Jul 202310:30 amRNSHolding(s) in Company
27th Jul 20237:00 amRNSInterim Results
4th Jul 20233:00 pmRNSDirectorate Change
22nd Jun 20237:00 amRNSHolding(s) in Company
10th May 20232:56 pmRNSResult of AGM
10th May 202312:00 pmRNSAGM Statement
10th May 20237:00 amRNSAppointment of Independent Non-Executive Director
13th Apr 20233:42 pmRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSFinal Results for the year ended 31 December 2022
16th Dec 20227:00 amRNSLong Term Incentive Plan Awards
7th Dec 20224:59 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSAppointment of Chief Executive
29th Jul 20221:54 pmRNSHolding(s) in Company
28th Jul 20227:00 amRNSInterim Report
24th May 20223:02 pmRNSRe Dividend
17th May 20224:01 pmRNSResult of AGM
12th Apr 20227:00 amRNSFinal Results for the year ended 31 December 2021
29th Mar 20224:40 pmRNSDeath of a Director
18th Mar 20224:45 pmRNSDirector's Leave of Absence
15th Nov 20217:00 amRNSChange of Auditor
7th Sep 20213:40 pmRNSHolding(s) in Company
30th Jul 20217:00 amRNSInterim Report
24th Jun 202112:22 pmRNSHolding(s) in Company
19th May 20213:34 pmRNSAppointment of Director and Company Secretary
12th May 20213:59 pmRNSResult of AGM
29th Apr 20215:04 pmRNSHolding(s) in Company
29th Apr 20214:50 pmRNSHolding(s) in Company
21st Apr 202111:39 amRNSHolding(s) in Company
15th Mar 20211:58 pmRNSDirectorate Change
4th Mar 20217:30 amRNSFinal results for the year ended 31 December 2020
30th Jul 20207:00 amRNSInterim Report
14th May 20202:17 pmRNSResult of AGM
1st May 20205:07 pmRNSAnnual General Meeting update
26th Mar 202012:18 pmRNSCovid-19 trading update, dividend and AGM
5th Mar 20205:47 pmRNSTypo correction to Final Results
5th Mar 20207:00 amRNSFinal results for the year ended 31 December 2019
14th Nov 20191:52 pmRNSGrant of Options
5th Aug 201910:47 amRNSHolding(s) in Company
2nd Aug 20197:00 amRNSInterim report for the six months ended 30 June 19
9th May 20193:20 pmRNSResult of AGM
5th Apr 201911:42 amRNSDirector/PDMR Shareholding
7th Mar 20197:00 amRNSPreliminary Results
4th Feb 20197:00 amRNSTrading Update
17th Aug 20187:00 amRNSHalf-year Report
25th Jul 201812:00 pmRNSDirectorate Change
2nd Jul 20183:21 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.